Public Health

17.05.18

UK risks being ‘second-tier state’ for drugs without post-Brexit EMA deal, MPs say

The government must “protect the UK’s status as a world leader for pharmaceuticals” in a future made uncertain by the ongoing Brexit negotiations, MPs have said today.

A report released by the Business, Energy and Industrial Strategy Committee (BEIS) argued that leaving the European Union without an agreement for the industry would diminish access to markets that bring £11.9bn of worth of exports to the economy and significantly impact the cost of drugs imported in from the EU.

No deal between both sides would risk a “hugely damaging effect” on the procurement of drugs coming in from the EU, of which the Union supplies almost three-quarters of the nation’s entire drug imports demanded by Brits.

The MPs said: “As a highly-regulated industry, the prospect of regulator divergence from the European Medicines Agency (EMA) is the deepest concern for the industry. Without a continued relationship, there is a significant risk of the UK being a second-tier state for new and innovative medicines.

“There are no benefits from regulatory divergence and no prospect of the industry being able to fully manage any divergence required in the time available for transition,” the report wrote.

If the UK departs from EMA regulations, the committee claimed the release of a new drug could cost as much as £45,000, putting the nation’s attractiveness for top pharmaceutical companies and professionals in doubt.

MPs called upon the government to keep the UK in the EMA as a priority when entering the Brexit negotiations. They concluded: “We have sought out any potential benefits to the UK pharmaceutical sector from Brexit, but found that any small gains would be hugely outweighed by additional costs or the loss of access to existing, successful markets.

“The best potential we found for the UK to remain and grow as a world leader in the development, manufacture and regulation of pharmaceuticals is to maintain as close as possible a relationship with the EU as possible.”

Rachel Reeves MP, chair of the BEIS Committee, said: “The government’s own analysis identifies pharmaceuticals as the sector for which UK/EU market access is the most important given the industry is reliant on friction-free border movement for their products. Any delays at the border faced by short-life pharmaceuticals for emergency treatments would have a hugely detrimental impact on patients.

“Some form of membership of the EMA is vital to the continued success of the pharma industry and to the welfare of British patients, and the government should strike a deal to keep some of the organisation’s jobs and facilities in the UK, to continue to share our world-leading expertise.”

Peter Ballard, chair of the British Generic Manufacturers Association, said the organisation fully supports the report’s key finding that Whitehall must secure a post-Brexit deal for the pharma industry “ensuring the closest possible regulatory alignment with the EU and the minimum border friction possible,” or else it risks harming patients.

“There is a real risk that the UK becomes a second tier country behind the US and the EU with the launch of new medicines being delayed due to different regulatory rules,” he concluded.

Image Credit: artisteer, iStock images

Enjoying NHE? Subscribe here to receive our weekly news updates or click here to receive a copy of the magazine!

Comments

There are no comments. Why not be the first?

Add your comment

 

national health executive tv

more videos >

latest healthcare news

One in six trusts could end PFI contracts due to poor performance as NHS heads for £1bn loss

19/10/2018One in six trusts could end PFI contracts due to poor performance as NHS heads for £1bn loss

A new report has revealed that 15% of all NHS trusts using private finance initiatives (PFI) could terminate contracts due to poor performance. ... more >
Council strips contract from NHS trusts and hands it to Virgin after High Court row

18/10/2018Council strips contract from NHS trusts and hands it to Virgin after High Court row

Lancashire County Council (LCC) has awarded a controversial £104m healthcare contract to Virgin Care for the second time after a hearing in... more >
Brand-new children’s hospital for Leeds as £450m plan revealed

18/10/2018Brand-new children’s hospital for Leeds as £450m plan revealed

New plans for a “world-class” children’s hospital site and a second state-of-the-art adult hospital building have been revealed... more >

editor's comment

25/09/2017A hotbed of innovation

This edition of NHE comes hot on the heels of this year’s NHS Expo which, once again, proved to be a huge success at Manchester Central. A number of announcements were made during the event, with the health secretary naming the second wave of NHS digital pioneers, or ‘fast followers’, which follow the initial global digital e... read more >

last word

Hard to be optimistic

Hard to be optimistic

Rachel Power, chief executive of the Patients Association, warns that we must be realistic about the very real effects of continued underfunding across the health service. It’s now bey... more > more last word articles >

the scalpel's daily blog

On your bike!

17/10/2018On your bike!

Sathish Sethuraman, travel and transport plan co-ordinator at Northumbria Healthcare NHS FT, explains how efforts to promote cycling to work at the trust are resulting in more staff travelling on two wheels. At Northumbria Healthcare, we are committed to becoming a greener organisation and reducing the environmental impact of delivering p... more >
read more blog posts from 'the scalpel' >

comment

Recoup and recover

10/10/2018Recoup and recover

The ease and round-the-clock nature of making cashless payments has transformed the way we pay for goods and services – and, from now on, t... more >
The clinical voice at the heart of procurement

10/10/2018The clinical voice at the heart of procurement

Jo Gander, director of the Clinical and Product Assurance (CaPA) team, talks about their role as part of the new NHS Supply Chain. NHS Suppl... more >
Deal or no deal?

10/10/2018Deal or no deal?

Dr Andrew Dearden, BMA treasurer and Brexit lead, takes a look at what different Brexit scenarios could means for both patients and healthcare pr... more >
A push for digital in mental health

10/10/2018A push for digital in mental health

Sean Duggan, chief executive of NHS Confederation’s Mental Health Network, argues that mental health services could hugely benefit from dig... more >

interviews

Duncan Selbie: A step on the journey to population health

24/01/2018Duncan Selbie: A step on the journey to population health

The NHS plays a part in the country’s wellness – but it’s far from being all that matters. Duncan Selbie, chief executive of Pu... more >
Cutting through the fake news

22/11/2017Cutting through the fake news

In an era of so-called ‘fake news’ growing alongside a renewed focus on reducing stigma around mental health, Paul Farmer, chief exec... more >
Tackling infection prevention locally

04/10/2017Tackling infection prevention locally

Dr Emma Burnett, a lecturer and researcher in infection prevention at the University of Dundee’s School of Nursing and Midwifery and a boar... more >
Scan4Safety: benefits across the whole supply chain

02/10/2017Scan4Safety: benefits across the whole supply chain

NHE interviews Gillian Fox, head of eProcurement (Scan4Safety) programme at NHS Supply Chain. How has the Scan4Safety initiative evolved sin... more >

health service focus

View all News